MiR-132 inhibition improves myocardial strain in a large animal model of chronic left ventricular adverse remodelling.

ABSTRACT:

Aims

Cardiac miR-132 has been proposed as a target for heart failure (HF) therapy. CDR132L, a rationally designed synthetic oligonucleotide inhibitor of miR-132 has proved pre-clinical efficacy in non-ischaemic and ischaemic large animal HF models. The safety and tolerability of CDR132L were tested in chronic HF patients in a Phase 1b study (NCT04045405) and is currently being tested in a Phase 2 trial in post-MI HF patients (NCT05350969). The aim of the current study was to gain further data on myocardial function and efficacy of CDR132L by analysing left ventricular (LV) and atrial (LA) wall motion by serial cardiac magnetic resonance (cMRI) strain imaging in a clinically relevant large animal (pig) model of chronic HF.

Methods and results

Animals (15 per group) were rando

SUBMITTER: Batkai S 

PROVIDER: S-EPMC12318716 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature